Skip to content
2000
image of miR-507 Acts as a Tumor Suppressor in Renal Cell Carcinoma Cells by Targeting STEAP3

Abstract

Introduction

In recent years, there has been a rise in the incidence of renal cell carcinoma (RCC), with metastatic RCC being a prevalent and significant contributor to mortality. While a regulatory role for microRNAs (miRNAs) in the development and progression of RCC has been recognized, their precise functions, molecular mechanisms, and potential clinical implications remain inadequately elucidated. Hence, this study aimed to explore the role of miR-507 in RCC and identify STEAP3 as a downstream target of miR-507.

Methods

Bioinformatics analysis was used to analyze the expression of miR-507 and STEAP3 in RCC specimens. CCK-8, Transwell, and flow cytometry assays were used to assess the function of miR-507 in RCC cells. The connection between miR-507 and STEAP3 was confirmed through a luciferase reporter assay. The expression level of STEAP3, p53, and xCT was analyzed by western blotting.

Results

Bioinformatics analysis showed that miR-507 was expressed at low levels in RCC tissues and was linked to poor overall survival. STEAP3 was found to be significantly upregulated in RCC. Further, STEAP3 was shown to be targeted by miR-507. High levels of miR-507 reduced the expression of STEAP3, leading to stagnant cell viability, apoptosis, and migrative capacity. Whereas miR-507 knockdown reverted such a tendency. The study also discovered that miR-507 exerted its inhibitory effect through the op53/xCT pathway.

Conclusion

Within RCC, miR-507 modulates the expression of SETAP3/p53/xCT axis, exhibiting a tumor suppressive effect. These discoveries offer present prospective biomarkers for both surveillance and treatment of RCC.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cchts/10.2174/0113862073353340241108053733
2025-01-09
2025-09-10

  • From This Site

    /content/journals/cchts/10.2174/0113862073353340241108053733
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Siegel R.L. Miller K.D. Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 2020 70 1 7 30 10.3322/caac.21590
    [Google Scholar]
  2. Sung H. Ferlay J. Siegel R.L. Laversanne M. Soerjomataram I. Jemal A. Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021 71 3 209 249 10.3322/caac.21660
    [Google Scholar]
  3. Rassy E. Parent P. Lefort F. Boussios S. Baciarello G. Pavlidis N. New rising entities in cancer of unknown primary: Is there a real therapeutic benefit? Crit. Rev. Oncol. Hematol. 2020 147 102882 10.1016/j.critrevonc.2020.102882
    [Google Scholar]
  4. Gill I.S. Cacciamani G.E. Duddalwar V. Thangathurai D. Cunningham M. Renal cancer with extensive level IV intracardiac tumour thrombus removed by robot. Lancet 2020 396 10262 e88 10.1016/S0140‑6736(20)32291‑1
    [Google Scholar]
  5. Hsieh J.J. Purdue M.P. Signoretti S. Swanton C. Albiges L. Schmidinger M. Heng D.Y. Larkin J. Ficarra V. Renal cell carcinoma. Nat. Rev. Dis. Primers 2017 3 1 17009 10.1038/nrdp.2017.9
    [Google Scholar]
  6. Blick C. Ritchie A.W.S. Eisen T. Stewart G.D. Improving outcomes in high-risk, nonmetastatic renal cancer: New data and ongoing trials. Nat. Rev. Urol. 2017 14 12 753 759 10.1038/nrurol.2017.123
    [Google Scholar]
  7. Marchioni M. Rivas J.G. Autran A. Socarras M. Albisinni S. Ferro M. Schips L. Scarpa R.M. Papalia R. Esperto F. Biomarkers for renal cell carcinoma recurrence: State of the art. Curr. Urol. Rep. 2021 22 6 31 10.1007/s11934‑021‑01050‑0
    [Google Scholar]
  8. Brown J.E. Royle K-L. Gregory W. Ralph C. Maraveyas A. Din O. Eisen T. Nathan P. Powles T. Griffiths R. Jones R. Vasudev N. Wheater M. Hamid A. Waddell T. McMenemin R. Patel P. Larkin J. Faust G. Martin A. Swain J. Bestall J. McCabe C. Meads D. Goh V. Wah M.T. Brown J. Hewison J. Selby P. Collinson F. Carser J. Srinivasan G. Thistlewaite F. Azzabi A. Beresford M. Farrugia D. Decatris M. Thomas C. Gale J. McAleer J. Clayton A. Boleti E. Geldart T. Sundar S. Lester J. Palaniappan N. Hingorani M. Rehman K. Khan M. Sarwar N. Graham J. Thomson A. Srihari N. Sheehan D. Srinivasan R. Khan O. Worlding J.A.S. Boussios S. Stuart N. Smith M.C. Danwata F. McLaren D. Sundaramurthy A. Lydon A. Beesley S. Lees K. Varughese M. Gray E. Scott A. Baxter M. Mullard A. Innominato P. Kapur G. Kumar A. Charnley N. Manetta C. Chakraborti P. Das P. Rudman S. Taylor H. Mikropoulos C. Highley M. Muthukumar D. Zarkar A. Vergis R. Sriprasad S. Brulinski P. Clarke A. Osbourne R. Harvey M. Dega R. Sparrow G. Barthakur U. Beaumont E. Manetta C. Michael A. Porfiri E. Azam F. Kodavtiganti R. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): An open-label, non-inferiority, randomised, controlled, phase 2/3 trial. Lancet Oncol. 2023 24 3 213 227 10.1016/S1470‑2045(22)00793‑8
    [Google Scholar]
  9. Campi R. Sessa F. Corti F. Carrion D.M. Mari A. Amparore D. Mir M.C. Fiori C. Papalia R. Kutikov A. Volpe A. Capitanio U. Pierorazio P.M. Scarpa R.M. Porpiglia F. Minervini A. Serni S. Esperto F. Triggers for delayed intervention in patients with small renal masses undergoing active surveillance: A systematic review. Minerva Urol. Nefrol. 2020 72 4 389 407 10.23736/S0393‑2249.20.03870‑9
    [Google Scholar]
  10. Chipman L.B. Pasquinelli A.E. miRNA targeting: Growing beyond the seed. Trends Genet. 2019 35 3 215 222 10.1016/j.tig.2018.12.005
    [Google Scholar]
  11. Hill M. Tran N. miRNA interplay: Mechanisms and consequences in cancer. Dis. Model. Mech. 2021 14 4 dmm047662 10.1242/dmm.047662
    [Google Scholar]
  12. Zheng Z. Zeng X. Zhu Y. Leng M. Zhang Z. Wang Q. Liu X. Zeng S. Xiao Y. Hu C. Pang S. Wang T. Xu B. Peng P. Li F. Tan W. CircPPAP2B controls metastasis of clear cell renal cell carcinoma via HNRNPC-dependent alternative splicing and targeting the miR-182-5p/CYP1B1 axis. Mol. Cancer 2024 23 1 4 10.1186/s12943‑023‑01912‑w
    [Google Scholar]
  13. Cen J. Liang Y. Feng Z. Chen X. Chen J. Wang Y. Zhu J. Xu Q. Shu G. Zheng W. Liang H. Wang Z. Deng Q. Cao J. Luo J. Jin X. Huang Y. Hsa_circ_0057105 modulates a balance of epithelial‐mesenchymal transition and ferroptosis vulnerability in renal cell carcinoma. Clin. Transl. Med. 2023 13 8 e1339 10.1002/ctm2.1339
    [Google Scholar]
  14. Choi S. Kim K. Yeo H. Lee G. Kim I. Oh J. An H-J. Lee S. miR-4284 functions as a tumor suppressor in renal cell carcinoma cells by targeting glutamate decarboxylase 1. Cancers 2023 15 15 3888 10.3390/cancers15153888
    [Google Scholar]
  15. Kalantzakos T. Hooper K. Das S. Sullivan T. Canes D. Moinzadeh A. Christ R.K. MicroRNA-155-5p targets JADE-1, promoting proliferation, migration, and invasion in clear cell renal cell carcinoma cells. Int. J. Mol. Sci. 2023 24 9 7825 10.3390/ijms24097825
    [Google Scholar]
  16. Poma M.J. Fuertes T.L. Camacho L.E. Moros Z.A. Vacas L.R. Herrera L.M.I. Fernandez P.A. Vara F.J.Á. Arranz E.E. Pozo G.A. Marín P.Á. MiRNAs in renal cell carcinoma. Clin. Transl. Oncol. 2022 24 11 2055 2063 10.1007/s12094‑022‑02866‑z
    [Google Scholar]
  17. Fard G.S. Farsani S.Z. Branicki W. Taheri M. MicroRNA signature in renal cell carcinoma. Front. Oncol. 2020 10 596359 10.3389/fonc.2020.596359
    [Google Scholar]
  18. Lv H.L. Li Z.L. Song Y.B. MicroRNA-507 represses the malignant behaviors of non-small cell lung cancer via targeting zinc finger E-box binding homeobox 2. Eur. Rev. Med. Pharmacol. Sci. 2019 23 22 9955 9964
    [Google Scholar]
  19. Wang S. Li J. Yang X. Coding L.N.R.N.A. Long non-coding RNA LINC00525 promotes the stemness and chemoresistance of colorectal cancer by targeting MIR-507/ELK3 axis. Int. J. Stem Cells 2019 12 2 347 359 10.15283/ijsc19041
    [Google Scholar]
  20. Jia L. Liu W. Cao B. Li H. Yin C. MiR-507 inhibits the migration and invasion of human breastcancer cells through Flt-1 suppression. Oncotarget 2016 7 24 36743 36754 10.18632/oncotarget.9163
    [Google Scholar]
  21. Sun C. Li G. Liu M. A novel circular RNA, circ_0005394, predicts unfavorable prognosis and contributes to hepatocellular carcinoma progression by regulating miR-507/E2F3 and miR-515-5p/CXCL6 signaling pathways. Onco. Targ. Ther. 2020 13 6171 6180 10.2147/OTT.S256238
    [Google Scholar]
  22. Xu M. Evans L. Bizzaro C.L. Quaglia F. Verrillo C.E. Li L. Stieglmaier J. Schiewer M.J. Languino L.R. Kelly W.K. STEAP1–4 (Six-Transmembrane Epithelial Antigen of the Prostate 1–4) and their clinical implications for prostate cancer. Cancers 2022 14 16 4034 10.3390/cancers14164034
    [Google Scholar]
  23. Passer B.J. Portebois N.V. Amzallag N. Prieur S. Cans C. de Climens R.A. Fiucci G. Bouvard V. Tuynder M. Susini L. Morchoisne S. Crible V. Lespagnol A. Dausset J. Oren M. Amson R. Telerman A. The p53-inducible TSAP6 gene product regulates apoptosis and the cell cycle and interacts with Nix and the Myt1 kinase. Proc. Natl. Acad. Sci. 2003 100 5 2284 2289 10.1073/pnas.0530298100
    [Google Scholar]
  24. Wu J. Bi Q. Zheng X. Cao H. Hao C. Sun Z. Wang W. STEAP3 can predict the prognosis and shape the tumor microenvironment of clear cell renal cell carcinoma. BMC Cancer 2022 22 1 1204 10.1186/s12885‑022‑10313‑z
    [Google Scholar]
  25. Boussios S. Devo P. Goodall I.C.A. Sirlantzis K. Ghose A. Shinde S.D. Papadopoulos V. Sanchez E. Rassy E. Ovsepian S.V. Exosomes in the diagnosis and treatment of renal cell cancer. Int. J. Mol. Sci. 2023 24 18 14356 10.3390/ijms241814356
    [Google Scholar]
  26. Fang X. Pan A. MiR-507 inhibits the progression of gastric carcinoma via targeting CBX4-mediated activation of Wnt/β-catenin and HIF-1α pathways. Clin. Transl. Oncol. 2022 24 10 2021 2028 10.1007/s12094‑022‑02862‑3
    [Google Scholar]
  27. Zhou R. Xu J. Wang L. Li J. LncRNA PRRT3-AS1 exerts oncogenic effects on nonsmall cell lung cancer by targeting microRNA-507/homeobox B5 axis. Oncol. Res. 2021 29 6 411 423 10.32604/or.2022.026236
    [Google Scholar]
  28. Wei Y. Sun Q. Zhao L. Wu J. Chen X. Wang Y. Zang W. Zhao G. LncRNA UCA1-miR-507-FOXM1 axis is involved in cell proliferation, invasion and G0/G1 cell cycle arrest in melanoma. Med. Oncol. 2016 33 8 88 10.1007/s12032‑016‑0804‑2
    [Google Scholar]
  29. Aweys H. Lewis D. Sheriff M. Rabbani R.D. Lapitan P. Sanchez E. Papadopoulos V. Ghose A. Boussios S. Renal cell cancer – Insights in drug resistance mechanisms. Anticancer Res. 2023 43 11 4781 4792 10.21873/anticanres.16675
    [Google Scholar]
  30. Ohgami R.S. Campagna D.R. McDonald A. Fleming M.D. The Steap proteins are metalloreductases. Blood 2006 108 4 1388 1394 10.1182/blood‑2006‑02‑003681
    [Google Scholar]
  31. Deng P. Li J. Lu Y. Hao R. He M. Li M. Tan M. Gao P. Wang L. Hong H. Tao J. Lu M. Chen C. Ma Q. Yue Y. Wang H. Tian L. Xie J. Chen M. Luo Y. Yu Z. Zhou Z. Pi H. Chronic cadmium exposure triggered ferroptosis by perturbing the STEAP3-mediated glutathione redox balance linked to altered metabolomic signatures in humans. Sci. Total Environ. 2023 905 167039 10.1016/j.scitotenv.2023.167039
    [Google Scholar]
  32. Huang J. Liu W. Song S. Li J.C. Gan K. Shen C. Holzbeierlein J. Li B. The iron-modulating hormone hepcidin is upregulated and associated with poor survival outcomes in renal clear cell carcinoma. Front. Pharmacol. 2022 13 1080055 10.3389/fphar.2022.1080055
    [Google Scholar]
  33. Ye C.L. Du Y. Yu X. Chen Z.Y. Wang L. Zheng Y.F. Liu X.H. STEAP3 affects ferroptosis and progression of renal cell carcinoma through the p53/xCT pathway. Technol. Cancer Res. Treat. 2022 21 15330338221078728 10.1177/15330338221078728
    [Google Scholar]
  34. Han Y. Fu L. Kong Y. Jiang C. Huang L. Zhang H. STEAP3 affects ovarian cancer progression by regulating ferroptosis through the p53/SLC7A11 pathway. Mediators Inflamm. 2024 2024 1 12 10.1155/2024/4048527
    [Google Scholar]
  35. Wei H. Li Z. Zhao Y. Zhu S. Wen S. Quan C. Six‐transmembrane epithelial antigen of prostate 3 (STEAP3) is a potential prognostic biomarker in clear cell renal cell carcinoma that correlates with M2 macrophage infiltration and epithelial–mesenchymal. Cancer Rep. 2023 6 8 e1824 10.1002/cnr2.1824
    [Google Scholar]
/content/journals/cchts/10.2174/0113862073353340241108053733
Loading
miR-507 Acts as a Tumor Suppressor in Renal Cell Carcinoma Cells by Targeting STEAP3
Bentham Science Publishers ; https://doi.org/10.2174/0113862073353340241108053733
/content/journals/cchts/10.2174/0113862073353340241108053733
/content/journals/cchts/10.2174/0113862073353340241108053733
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: STEAP3 ; proliferation ; MiR-507 ; renal cell carcinoma ; invasion ; metastasis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test